MARKET

CTXRW

Citius Pharmaceuticals Inc
CTXRW
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-1.5559
-
0.1791
-
Citius Oncology Announces Warrant and Share Issuance in $18 Million Offering
Reuters · 12/10 22:29
Citius Oncology Sells Shares and Warrants in $18 Million Private Placement
Reuters · 12/09 13:45
CITIUS ONCOLOGY INC - PROCEEDS SUPPORT LAUNCH OF LYMPHIR FOR CUTANEOUS T-CELL LYMPHOMA
Reuters · 12/09 13:30
CITIUS ONCOLOGY INC - TO PURCHASE 1,284,404 SHARES OF COMMON STOCK AT $1.09 PER SHARE IN DIRECT OFFERING
Reuters · 12/09 13:30
CITIUS ONCOLOGY INC - ER-KIM TO BE EXCLUSIVE DISTRIBUTOR OF LYMPHIR IN TURKEY AND GCC
Reuters · 12/04 13:37
Citius Oncology Unveils Corporate Presentation Highlighting Launch of LympHIR for Cutaneous T-Cell Lymphoma
Reuters · 12/01 21:47
Citius Pharmaceuticals Highlights Oncology Pipeline and LYMPHIR Launch in New Corporate Presentation
Reuters · 12/01 21:42
CITIUS ONCOLOGY ANNOUNCES U.S. COMMERCIAL LAUNCH OF LYMPHIR™, A NOVEL CANCER IMMUNOTHERAPY FOR CUTANEOUS T-CELL LYMPHOMA (CTCL)
Reuters · 12/01 17:00
More

Webull offers Citius Pharmaceuticals Inc stock information, including NASDAQ: CTXRW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTXRW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CTXRW stock methods without spending real money on the virtual paper trading platform.